Bulletin
Investor Alert

New York Markets Close in:

Topics

Huntington's Disease

10:03 a.m. Feb. 8, 2021 - By Jaimy Lee
UniQure's stock rallies 7% on positive safety data for Huntington's disease treatmentShares of UniQure gained 7.2% in trading on Monday after the company said an independent data safety monitoring board said there were no safety concerns in a Phase 2/3 clinical trial for its experimental Huntington's disease treatment. The board has reviewed six months of safety data for the first two patients enrolled in the randomized, double-blind study. UniQure said it expects to enroll six more patients who have been diagnosed with the rare neurodegenerative disease by mid-2021. The investigational gene therapy is called AMT-130. "While early, we remain bullish about uniQure's [Huntington's disease] gene therapy and continue to believe the program is nearly all upside from current levels," Raymond James analyst Danielle Brill wrote in a note to investors. Uniqure's stock is down 35.9% for the past year, while the broader S&P 500 has gained 16.5%.
4:40 a.m. Sept. 22, 2020 - By Jaimy Lee
Vaccinex's stock falls after investigational drug fails Huntington's disease studyShares of Vaccinex Inc. tumbled 61.6% in premarket trading on Tuesday after the preclinical biotechnology company said an experimental Huntington's disease treatment, pepinemab, did not meet the primary endpoints in a Phase 2 double-blind, placebo-controlled clinical trial. Earlier this month, Vaccinex had announced plans to study pepinemab in combination with Merck & Co. Inc.'s Keytruda as a possible treatment for advanced forms of metastatic head and neck squamous cell carcinoma. Vaccinex's stock is up 12.8% so far this year. The S&P 500 has gained 1.5%.
Browse topics:

Filter results by

Location

Us (4)

Europe (2)

Eu (1)

Link to MarketWatch's Slice.